Rizatriptan-d6 (benzoate)

• Description:

  Rizatriptan-d6 (benzoate) is the deuterium labeled Rizatriptan benzoate. Rizatriptan benzoate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system[2].

• UNSPSC:

  12352005

• Target:

  5-HT Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling; Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  C(O)(=O)C1=CC=CC=C1.C(CN(C([2H])([2H])[2H])C([2H])([2H])[2H])C=1C=2C(NC1)=CC=C(CN3C=NC=N3)C2

• Molecular Formula:

  C22H19D6N5O2

• Molecular Weight:

  397.50

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Sciberras DG, et al. Initial human experience with MK-462 (rizatriptan) : a novel 5-HT1D agonist. Br J Clin Pharmacol. 1997 Jan;43 (1) :49-54.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• Isoform:

  5-HT1 Receptor

• CAS Number:

  [1216984-85-8]